• Projected market demand leads to production capacity addition• UCB to build new biotech manufacturing unit in Bulle, Switzerland
Brussels (Belgium), 22 December 2010, 7.00 AM (CET) – regulated information – UCB announced today that the company has initiated a project to build in-house biotech microbial manufacturing capacity in Bulle, Switzerland to secure demand for its core product Cimzia® (certoluzimab pegol). The new manufacturing unit should be operational in 2015 and requires an investment of EUR 250 million in two steps.
For further informationAntje Witte, Investor Relations UCBT +32.2.559.9414, email@example.com Michael Tuck-Sherman, Investor Relations, UCBT +32.2.559.9712, firstname.lastname@example.org Nancy Nackaerts, External Communications, UCBT +32.473.864.414 or +32.2.559.92.64, email@example.com
About UCBUCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).Forward looking statements This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.
UCB to expand manufacturing capacity for Cimzia®
UCB breidt productiecapaciteit voor Cimzia® uit
UCB prévoit d'étendre sa capacité de production pour Cimzia®
© 2007 - 2013 UCB S.A., Belgium. All rights reserved.